Trials / Approved For Marketing
Approved For MarketingNCT03245528
Expanded Access for LJPC-501
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- La Jolla Pharmaceutical Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.
Detailed description
Primary Objective The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy. Secondary Objective The secondary objective of the study is to assess the safety of LJPC-501.
Conditions
- Catecholamine Resistant Hypotension (CRH)
- Distributive Shock
- High Output Shock
- Sepsis
- Vasodilatory Shock
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LJPC-501 | angiotensin II |
Timeline
- First posted
- 2017-08-10
- Last updated
- 2018-03-08
Source: ClinicalTrials.gov record NCT03245528. Inclusion in this directory is not an endorsement.